Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  6.00 2.86% 216.00 207,416 16:35:09
Bid Price Offer Price High Price Low Price Open Price
212.00 216.00 220.00 204.00 210.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -20.53 -26.20 169
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:09 UT 6 216.00 GBX

Silence Therapeutics (SLN) Latest News

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
07/10/201909:07Silence Therapeutics (the old SR Pharma)48,010
08/8/201906:43Lets Short This Duffer Out Of Business704
06/10/201609:04Gower Productions Presents ....."PREDICTA BID"52
05/10/201620:29port-
29/5/201310:32Silence Therapeutics - news and views1,412

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:35:09216.00612.96UT
15:29:08212.005971,265.64AT
15:29:05212.00296627.52AT
15:29:05212.002,0004,240.00AT
15:28:04206.005971,229.82AT
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

DateSubject
15/10/2019
09:20
Silence Therapeutics Daily Update: Silence Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 210p.
Silence Therapeutics Plc has a 4 week average price of 165p and a 12 week average price of 152p.
The 1 year high share price is 256p while the 1 year low share price is currently 40p.
There are currently 78,094,027 shares in issue and the average daily traded volume is 78,298 shares. The market capitalisation of Silence Therapeutics Plc is £168,683,098.32.
28/9/2019
13:44
tshirley12: Thanks for those responses,obviously many factors at play.its just that having waited so long for the share price to increase on genuine positive news,the feeling of frustration that MMs are now playing games with it.
27/9/2019
21:32
1gw: In terms of price action, who knows what drives the market? Doubtless the technicals played a part, but I also think there was probably some unease caused by the curious position of Malinckrodt - its own share price (and bond prices) cratering under heavy short selling and fears of it filing for chapter 11 bankruptcy protection due to opioid litigation and a dispute on drug pricing. What impact Ch 11 for MNK would have on Silence, I don't know, but perhaps it could impact the realisation of some of the milestone payments if it occurred at a bad time. I chose not to sell any this time round. There are a few potential near-term catalysts which could drive another spike and I didn't want to miss one if it happened. My hope is that we're following the ARWR path, a couple of years or so behind. I bought into ARWR, following the SLN purchase of ARWR shares, and sold out again after a decent rise (about a 40% average gain). But ARWR had a tremendous rise and those who held through the dips were very well rewarded - even after it has come off a bit recently, it is still around 10x higher than when I sold out. Potential near-term catalysts that I can see are: o Quark QP-1002 (DGF) outcome of negotiations with FDA on transition to New Drug Application process following completion of Phase III trials - expected this year (and possibly also Quark IPO which would invite valuation comparisons). o Announcement of licensing deal on LP(a) asset SLN360. Silence may fund the Phase 1 trial itself, but if it can get a good enough deal to license it then it may just do that instead. o Announcement of MNK exercising an option on another Complement asset. o Announcement of a licensing/collaboration deal on one of its extra-hepatic delivery assets/concepts. And of course, selling the company to big pharma (or another RNAi company) isn't entirely out of the question, although I suspect the company might think it would do better to get the share price up first by making progress on some of the above and perhaps taking SLN124 through at least Phase 1. One catalyst I thought might be coming up, a Silence IPO, sounds as though it's not on the near-term agenda, given David Solomon's comments on today's podcast.
18/9/2019
19:25
1gw: Time for a bit of idle M&A speculation? In January 2017, when Ali parked the Silence tanks on Arrowhead's lawn ("potential corporate transaction" and "product licensing" mentioned in press release, among other things), he bought 9% of the company (ARWR) at an average of around $1.65/share. At the time Silence was around £1/share I think. Today ARWR is trading at around $28.85/share and Silence closed at £2.40. The xrate is about the same (Jan 2017 vs today) at £1=$1.25. So ARWR has gone up around 17.5 times, while SLN has done a bit better than doubled since the announcement of SLN's purchase of the ARWR position. In 2017, ARWR was so worried about the SLN move that it put in place a poison pill if I recall correctly. So, economic logic to one side for a minute, can you imagine the satisfaction in the ARWR C-suite if they could pick up SLN for a fraction of what they might have been looking at in terms of a corporate transaction back in 2017 (in terms of share exchange ratio), when they scrambled to put defences in place? But then look at the economic logic. At the recent R&D event we had SLN trumpeting it's LP(a) asset SLN360, which appears to be a potential competitor of the ARWR/Amgen AMG890 asset. So acquisition of SLN would remove the LP(a) competition threat, enabling ARWR to choose the best LP(a) asset - maybe even manage the transition from AMG890, which should be available first, to SLN360 which might be superior. Also it would remove the risk of any patent disputes with Silence, and ARWR would be in a position to take the best from each company's platforms. And perhaps best of all, ARWR might judge it would be positioned to capture a decent chunk of the upside from Silence asset success, if it thinks the SLN market value has the potential to follow ARWR's shareprice trajectory of the last couple of years as the SLN assets move into and through the clinic. You then look at the SLN shareholder base. Around 50% of the company (I estimate) held between Ali, Griffiths, Keith and Quested. So fairly easy to see who ARWR need to get onside if they want a deal to happen. It seems to me ARWR could quite easily justify a really juicy multiple of the current SLN share price to get SLN in an all-paper (or largely paper) transaction. Whether they could offer enough to convince Ali & co that it was an attractive alternative to going it alone, I don't know, but it seems to me it is a reasonable possibility. Post offered to try to provoke some reaction/discussion. Errors excepted, and no advice intended.
01/8/2019
09:19
1gw: So can we hope that that is the consolidation done and the share price is ready to resume its rise again?
19/7/2019
15:30
frndlyfire: Eagle is in for a nice surprise when he checks the share price! Well done to all the LT holders here. A lot of pain, but finally something to smile about!
18/7/2019
13:20
herb clark: Really don't understand why the share price is not higher. Can anyone think any downsides?
24/4/2019
07:47
tarlok: So we see how much notice the MM make of FT news article on SLN , price change of 1p
22/3/2019
10:32
tshirley12: A few questions,would appreciate any comments.Firstly over the last year the share price has fallen from a peak of 250p to less than 50p.today.Whilst Arrowheads share price as more or less quadrupled,what is Silence doing that is fundamentally different to justify the crash. What other assets does Silence have other than their.I.P. Is there a danger of Silence running out of funding,and when. As anybody got any idea how much they received from their Alnylam agreement. What happened to ATUO27. As there's no sign of a takeover,are there any possibilities of a merger with anybody. Now waiting on the results from Quark,if this doesn't go as well as hoped, where does that leave us. As I said I would appreciate any comments as I am looking at all avenues before I decide to bail out.
05/10/2018
17:37
1gw: Interesting to compare the shares on loan position with the share price chart. According to Euroclear, SoL monthly average this year is as follows: 1.4m Jan (average shares on loan) 1.4m Feb 2.6m Mar 4.3m Apr 4.2m May 4.2m Jun 4.1m Jul 3.9m Aug 2.3m Sep So it looks like a significant increase in short positions in March and April (assuming the SoL correlates to short positions) may have helped to knock the shareprice off its 200p perch. hTtps://my.euroclear.com/apps/en/monthly-stock-loan-data.html#month=eq:9&year=eq:2018&limit=0&search=1&order=asc:abbreviation
04/5/2017
16:00
1gw: ARWR is up around 20% this afternoon - not enough to take me into profit on my holding, but makes the loss look a little less severe. They beat on revenue and earnings, thanks (I think) to the Amgen up-front payments, and also announced an analyst R&D day for September to explain what they're doing. They described the Amgen partnership as working well and said in response to a question that they were interested in similar partnerships with other companies and are optimistic that they can enter into additional strategic partnerships. No obvious follow-through to the SLN share price yet, but perhaps ARWR's spike (on heavy volume) will draw some attention to other companies in the sector.
Silence Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191015 21:01:25